Gene therapy of cancer - 12th International Conference.

Research output: Contribution to journalArticle

Abstract

The 12th International Conference on Gene Therapy of Cancer, sponsored by the Sidney Kimmel Cancer Center, was organized by Robert E Sobol and Kevin Scanlon, and centered on the development and use of viral vectors as therapeutics. The emphasis of this report is on translational and clinical studies, primarily focused on delivery strategies rather then tumor antigens. In many instances, transduced/transfected cells were used to deliver the transgene, including not only dendritic cells as professional antigen-presenting cells, but also transfected autologous and allogenic tumor cells. In addition, immune augmentation with cytokines and growth factor transgenes, including the recently cloned proteins IL-23 and IL-24, were discussed, as was the use of antisense to TGFbeta2 to overcome tumor-associated immunosuppression. The majority of speakers discussed strategies using viral vectors, although strategies with electroporation, minimalistic immunogenically defined gene expression vectors and plasmids were also mentioned. Adenoviruses were the predominating viral vector, although pox viral, herpes simplex viral, retroviral and lentiviral vectors were also used.

Original languageEnglish (US)
Pages (from-to)100-104
Number of pages5
JournalIDrugs : the investigational drugs journal
Volume7
Issue number2
StatePublished - Feb 2004

Fingerprint

Genetic Therapy
Transgenes
Neoplasms
Interleukin-23
Herpes Simplex
Electroporation
Neoplasm Antigens
Antigen-Presenting Cells
Adenoviridae
Immunosuppression
Dendritic Cells
Intercellular Signaling Peptides and Proteins
Plasmids
Cytokines
Gene Expression
Proteins
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Gene therapy of cancer - 12th International Conference. / Talmadge, James E.

In: IDrugs : the investigational drugs journal, Vol. 7, No. 2, 02.2004, p. 100-104.

Research output: Contribution to journalArticle

@article{2a2edf8654494c4e919941c40cd3dfe9,
title = "Gene therapy of cancer - 12th International Conference.",
abstract = "The 12th International Conference on Gene Therapy of Cancer, sponsored by the Sidney Kimmel Cancer Center, was organized by Robert E Sobol and Kevin Scanlon, and centered on the development and use of viral vectors as therapeutics. The emphasis of this report is on translational and clinical studies, primarily focused on delivery strategies rather then tumor antigens. In many instances, transduced/transfected cells were used to deliver the transgene, including not only dendritic cells as professional antigen-presenting cells, but also transfected autologous and allogenic tumor cells. In addition, immune augmentation with cytokines and growth factor transgenes, including the recently cloned proteins IL-23 and IL-24, were discussed, as was the use of antisense to TGFbeta2 to overcome tumor-associated immunosuppression. The majority of speakers discussed strategies using viral vectors, although strategies with electroporation, minimalistic immunogenically defined gene expression vectors and plasmids were also mentioned. Adenoviruses were the predominating viral vector, although pox viral, herpes simplex viral, retroviral and lentiviral vectors were also used.",
author = "Talmadge, {James E}",
year = "2004",
month = "2",
language = "English (US)",
volume = "7",
pages = "100--104",
journal = "IDrugs",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - Gene therapy of cancer - 12th International Conference.

AU - Talmadge, James E

PY - 2004/2

Y1 - 2004/2

N2 - The 12th International Conference on Gene Therapy of Cancer, sponsored by the Sidney Kimmel Cancer Center, was organized by Robert E Sobol and Kevin Scanlon, and centered on the development and use of viral vectors as therapeutics. The emphasis of this report is on translational and clinical studies, primarily focused on delivery strategies rather then tumor antigens. In many instances, transduced/transfected cells were used to deliver the transgene, including not only dendritic cells as professional antigen-presenting cells, but also transfected autologous and allogenic tumor cells. In addition, immune augmentation with cytokines and growth factor transgenes, including the recently cloned proteins IL-23 and IL-24, were discussed, as was the use of antisense to TGFbeta2 to overcome tumor-associated immunosuppression. The majority of speakers discussed strategies using viral vectors, although strategies with electroporation, minimalistic immunogenically defined gene expression vectors and plasmids were also mentioned. Adenoviruses were the predominating viral vector, although pox viral, herpes simplex viral, retroviral and lentiviral vectors were also used.

AB - The 12th International Conference on Gene Therapy of Cancer, sponsored by the Sidney Kimmel Cancer Center, was organized by Robert E Sobol and Kevin Scanlon, and centered on the development and use of viral vectors as therapeutics. The emphasis of this report is on translational and clinical studies, primarily focused on delivery strategies rather then tumor antigens. In many instances, transduced/transfected cells were used to deliver the transgene, including not only dendritic cells as professional antigen-presenting cells, but also transfected autologous and allogenic tumor cells. In addition, immune augmentation with cytokines and growth factor transgenes, including the recently cloned proteins IL-23 and IL-24, were discussed, as was the use of antisense to TGFbeta2 to overcome tumor-associated immunosuppression. The majority of speakers discussed strategies using viral vectors, although strategies with electroporation, minimalistic immunogenically defined gene expression vectors and plasmids were also mentioned. Adenoviruses were the predominating viral vector, although pox viral, herpes simplex viral, retroviral and lentiviral vectors were also used.

UR - http://www.scopus.com/inward/record.url?scp=2442644314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442644314&partnerID=8YFLogxK

M3 - Article

C2 - 15057647

AN - SCOPUS:2442644314

VL - 7

SP - 100

EP - 104

JO - IDrugs

JF - IDrugs

SN - 1369-7056

IS - 2

ER -